Baillie Gifford Updates Alnylam Pharma Stake (SC 13G/A)
Ticker: ALNY · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1178670
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**Baillie Gifford just updated its Alnylam stake, watch for potential stock movement.**
AI Summary
Baillie Gifford & Co, a prominent investment management firm, filed an amended SC 13G/A on January 29, 2024, indicating a change in their ownership of Alnylam Pharmaceuticals, Inc. common stock. While the filing doesn't specify the exact change in share count or percentage, it signals an update to their previously reported holdings as of December 29, 2023. This matters to investors because large institutional ownership changes can influence stock price and reflect a major investor's updated outlook on the company's future prospects.
Why It Matters
This filing shows that a major institutional investor, Baillie Gifford & Co, has adjusted its position in Alnylam Pharmaceuticals, which can signal their updated confidence in the company's performance.
Risk Assessment
Risk Level: low — This filing is an update to an existing position by an institutional investor, not a new, aggressive stake, making it a low-risk event.
Analyst Insight
Investors should monitor future filings from Baillie Gifford & Co to understand the direction of their investment in Alnylam Pharmaceuticals, as significant changes could influence market sentiment.
Key Players & Entities
- Baillie Gifford & Co (company) — the investment firm filing the SC 13G/A
- ALNYLAM PHARMACEUTICALS, INC. (company) — the subject company whose stock is being reported
- 0001088875-24-000047 (dollar_amount) — accession number for the filing
- January 29, 2024 (date) — date the SC 13G/A was filed
- December 29, 2023 (date) — date of the event requiring the filing
Forward-Looking Statements
- Baillie Gifford & Co will continue to be a significant institutional holder of Alnylam Pharmaceuticals stock. (Baillie Gifford & Co) — high confidence, target: Q2 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No.4)' sections.
Which company is the subject of this filing?
The subject company is ALNYLAM PHARMACEUTICALS, INC., identified by 'COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.' and 'Name of Issuer: ALNYLAM PHARMACEUTICALS'.
Who filed this SC 13G/A?
This SC 13G/A was filed by BAILLIE GIFFORD & CO, as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAILLIE GIFFORD & CO' section.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Alnylam Pharmaceuticals is 02043Q107, as stated under 'CUSIP No. 02043Q107'.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 29, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) 29 December 2023'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).